Wells Fargo and Stifel say Moderna and Merck's Phase 3 cancer vaccine data could benefit Repligen, Danaher, Thermo Fisher, and Maravai LifeSciences. TEM stock is also surging.
The deal combines advanced cancer diagnostics with Tempus’ AI platform for improved surveillance.
Tempus AI announces research collaboration with Angiosarcoma Awareness, analyzing ~600 patient records with paired DNA/RNA data to accelerate rare cancer insights.
Tempus AI gets FDA approval for tumor-only cancer DNA test, making diagnosis easier and boosting future revenue potential.
Tempus AI revenue rose 36% to $348M, but losses widened. Stock fell ~7% after weaker profit and cautious outlook.
TD Cowen upgraded Tempus AI to Buy, $65 target, citing strong growth in AI pharma tools despite recent stock drop.
